Mimetas and Roche enter in a collaboration to develop human disease models for drug development
6.07.2021
Leiden, The Netherlands – 6 July 2021 – Mimetas, a leader in organ-on-a-chip-based disease models and technology, and Roche, a world-leading pharmaceutical company, announced today that they have entered a collaboration to develop human disease models to characterize novel compounds in inflammatory bowel disease (IBD) and hepatitis B virus infections (HBV). Under the terms of the agreement, Mimetas is eligible to receive an upfront payment and milestone payments from Roche.
Mimetas will be responsible for developing tissue-based disease models and assays in the OrganoPlate, its proprietary organ-on-a-chip platform that increases the predictability of biomarkers and reduces animal use in scientific testing. Roche will gain access to technology, disease models and scientific results. Roche will also receive an option to exclusively license specific disease models and assays for use in drug discovery.
"This exciting collaboration enables our Research & Early Development group to apply state-of-the-art organ-on-a-chip technology in the modelling of IBD and HBV. These models have the potential to improve our understanding of disease biology and transform our drug discovery process," said James Sabry, Global Head, Roche Pharma Partnering.
"The collaboration with Roche leverages our ongoing focus on developing predictive, phenotypic models, preceded by numerous successful projects over the last eight years," said Jos Joore, CEO of Mimetas. "We will leverage our disease modelling expertise in our world-leading OrganoPlate platform to gain novel insights in IBD and HBV. Working together with the outstanding Roche team, we hope to make a difference in the lives of patients."
Mimetas is a world leader in disease modelling using organ-on-a-chip technologies. Its proprietary OrganoPlate® platform enables the development and high-throughput screening of physiologically relevant disease models. The company offers its technology and know-how in therapy co-development projects, services and off-the-shelf products. Mimetas works with leading pharmaceutical and biotech companies worldwide to develop novel therapies for unresolved diseases. Mimetas was founded in 2013 in Leiden, the Netherlands, and has grown into a multinational company with operations in Asia, Europe and the United States.
Press Contacts
Jos JOORE – / Tel: +31 85 888 3161
OMX Europe Venture Fund* is a life science venture fund managed by Mérieux Equity Partners with the co-sponsorship of Korys (www.korys.be) and Mérieux Développement (www.merieux-partners.com). For more information feel free to contact:
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Anonymous statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
